Table 3.

Multivariate analyses of prognosis factors associated with survival

VariablesDFS
OS
Cancer-specific survival
HR (95% CI)PHR (95% CI)PHR (95% CI)P
A*
    FoxP3+ TILs (low vs high)1.93 (1.25-2.96)0.0032.45 (1.55-3.87)0.00012.68 (1.32-5.43)0.006
    Granzyme B+ TILs (low vs high)0.59 (0.38-0.90)0.0140.66 (0.42-1.03)0.0650.57 (0.29-1.12)0.10
    PD-L1 (low vs high)1.71 (1.11-2.65)0.0151.31 (0.84-2.07)0.241.06 (0.51-2.20)0.88
    PD-L2 (low vs high)0.96 (0.60-1.53)0.861.10 (0.68-1.79)0.710.77 (0.35-1.69)0.51
    Combined PD-Ls
        OverallNA0.22NA0.22NA0.71
        I vs II1.19 (0.78-1.82)0.421.05 (0.67-1.64)0.841.03 (0.54-1.99)0.92
        I vs III1.95 (0.90-4.23)0.092.03 (0.90-4.59)0.090.43 (0.05-3.49)0.43
B*
    FoxP3+ TILs1.01 (1.01-1.02)0.00082.45 (1.55-3.87)0.00011.02 (1.01-1.03)0.0049
    Granzyme B+ TILs0.99 (0.98-1.00)0.0120.99 (0.98-1.00)0.00470.98 (0.97-1.00)0.010
    PD-L11.01 (1.00-1.02)0.00971.00 (1.00-1.01)0.271.00 (0.99-1.01)0.76
    PD-L21.00 (0.99-1.00)0.361.00 (0.99-1.01)0.620.99 (0.98-1.01)0.30
C*
    FoxP3+ TILs (low vs high)1.74 (1.04-2.91)0.0341.63 (0.92-2.90)0.094ND
    PD-L1 (low vs high)2.06 (1.12-3.81)0.0201.84 (1.00-3.40)0.050ND
  • NOTE: Cox proportional hazards regression model, including all the clinicopathologic features as covariates (for details, see Supplementary Tables S1-S3).

    Abbreviations: NA, not applicable; ND, not done.

  • * (A) Patients were dichotomized according to the 75th percentile of PD-Ls density and median of TIL counts. (B) PD-Ls and TIL density were modeled as a continuous variable. The HR is for each increase of 5% in expression intensity. (C) Validation of the prognostic significance of PD-L1 and FoxP3+ TIL density in an independent data set.

  • Patients were divided into three groups: (a) both PD-L1 and PD-L2 were positive (n = 13), (b) either PD-L1 or PD-L2 was positive (n = 94), and (c) both PD-L1 and PD-L2 were negative (n = 133).